2068
Hydroxyurea (HU) and sodium phenylbutyrate (SPB) have been shown to increase fetal hemoglobin (Hb F) levels in patients with thalassemia intermedia.
 patients with thalassemia intermedia: Subject; hemoglobin (Hb F) levels: Effect; Hydroxyurea (HU) and sodium phenylbutyrate (SPB): Treatment; Hydroxyurea: Treatment.Drug; sodium phenylbutyrate: Treatment.Drug; thalassemia intermedia: Treatment.Disorder; Hydroxyurea: Combination.Drug; sodium phenylbutyrate: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients with thalassemia intermedia: Subject; hemoglobin (Hb F) levels: Effect; Hydroxyurea (HU) and sodium phenylbutyrate (SPB): Treatment; Hydroxyurea: Treatment.Drug; sodium phenylbutyrate: Treatment.Drug; thalassemia intermedia: Treatment.Disorder; Hydroxyurea: Combination.Drug; sodium phenylbutyrate: Combination.Drug